Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. (Q43001787)
Jump to navigation
Jump to search
scientific article published in August 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. |
scientific article published in August 2006 |
Statements
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment (English)
José M Sánchez-Tapias
Moisés Diago
Pedro Escartín
Jaime Enríquez
Manuel Romero-Gómez
Rafael Bárcena
Eva Martínez-Bauer
Ramón Pérez
Milagros Testillano
Ramón Planas
Ricard Solá
Manuel García-Bengoechea
Javier Garcia-Samaniego
Miguel Muñoz-Sánchez
Ricardo Moreno-Otero
TeraViC-4 Study Group
1 August 2006